Acetylon begins study of drug candidate for multiple myeloma

09/22/2011 | Mass High Tech (Boston)

Acetylon Pharmaceuticals initiated a Phase I-IIa clinical study of ACY-1215, a drug candidate for relapsed and relapsed-refractory multiple myeloma. Phase I tests the class 2 histone deacetylase inhibitor as a treatment alone and in combination with standard therapies. In Phase IIa, researchers will evaluate the cancer's response to the drug.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC